WILMINGTON, DE — NRx Pharmaceuticals Inc. said its HOPE Therapeutics subsidiary will become the first interventional psychiatry network to deploy Zeta Surgical’s newly FDA-cleared robotic transcranial magnetic stimulation system, expanding its use of precision-guided TMS ahead of a planned military and civilian trial combining the technology with NRX-101.
Clinical staff are undergoing orientation and training at Zeta Surgical’s Boston headquarters before the system is deployed at HOPE clinics in Florida.
The Zeta TMS Robotic System received FDA 510(k) clearance in July 2026. It uses AI-driven software and a robotic arm to track patient movement and adjust the TMS coil in real time with submillimeter precision…